Originator Developed by Eli Lilly Approval status Still investigational - Phase 3 trials are underway before any regulator decides on approval What it has been studied for Study areas from the published literature
Secondary changes related to the endothelial cell damage and/or obstruction of the sinusoids leading to local ischemia may be seen
A 'second wave' of GLP-1 development The insurer's 2026 pipeline report, which reviewed more than 440 new drug and supplemental submissions made to Health Canada in 2025, describes what it calls a second wave of GLP-1 innovation
A once-daily commitment to weight loss with the Wegovy pill Once-daily Wegovy pill dose-escalation schedule 1 Start your patients at the 1.5 mg dose, escalating the dose every 30 days until the 25 mg maintenance dose is reached
C.CorvinoV.MarcheseE.SerranoA.MichettiF.DambrosiN
Personalized Wellness Coaching - Receive one-on-one coaching and a personalized plan designed around your body, goals, and lifestyle